Research programme: FLT-3 tyrosine kinase inhibitors - NovartisAlternative Names: AST 487; FLT-3 tyrosine kinase inhibitors research programme - Novartis; NVP-AST487
Latest Information Update: 11 Aug 2011
At a glance
- Originator Novartis
- Class Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 11 Aug 2011 No development reported - Preclinical for Acute myeloid leukaemia in Switzerland (PO)
- 20 Apr 2005 Preclinical trials in Acute myeloid leukaemia in Switzerland (PO)